Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Abbot, AbbVie, absorbed, affinity, AI, altogether, amino, Amir, anesthesiologist, Apolipoprotein, Aramc, Armachol, AU, autocrine, Ayala, AYLA, bacteria, bacterial, Benson, bespoke, beta, Biden, bio, biomarker, Biond, Bowel, Bristol, calprotectin, Canaan, carefully, CDI, clostridium, closure, cohort, Colombel, colonization, commensurate, commonplace, Comverse, consortia, counterclaim, COVID, CRL, CT, culturing, cycle, Cytodyn, cytokine, Daniel, DAP, Democratic, Denver, destructive, difficile, discretionary, distancing, downsized, Dynavax, efficiacy, elderly, electoral, ELF, Eli, Enanta, endoscopic, entrepreneur, envisage, EP, Excellence, fecal, feedback, Feinberg, female, fermentation, Floor, flora, fluid, fluidity, Forer, furlough, Gabbay, Gannex, gastrointestinal, GBP, globe, Hanauer, Harkey, heightening, Hepion, hol, homologue, house, IBD, Ibex, IM, implicated, ingredient, inhibitor, interchangeable, Interleukin, inventorship, Joseph, Josephine, JP, judgement, Justin, Kasierer, Kost, Lautenberg, leadership, lending, lessor, leveraged, lifespan, Lilly, LLLP, loop, lottery, Macau, Mack, macrobiome, Mayo, megluine, meglumine, Merck, Metacrine, microbial, Mifal, misleading, Mortgage, movement, MTADV, MyLiveIn, Nantahala, Naor, Nessuah, NGM, NMPA, nonbinding, nonclinical, Northwestern, nurse, Oak, overrun, PAE, payout, peptide, persuasive, Pfizer, polymerization, Poshinksi, Poshinski, potent, Poxel, Primsa, prolonged, provoked, RA, readout, reconstitute, reexamination, Refaeli, refine, regime, remission, reopen, repertoire, resubmission, resumed, revoke, rheumatoid, SAA, Sagimet, SCD, sector, Senate, sequester, sera, Sheba, shipping, Shomron, shortly, spite, staffing, stimuli, sublicensing, subset, Suite, SuperDonor, switch, synovial, TATA, tech, temporarily, Therapix, Threonine, Transthyretin, trauma, TRPX, UK, ulcerative, unapproved, unequivocal, unfavorable, Valine, variant, variation, vehicle, wave, whichever, willexpire, Wilmot, workplace, Yissum, Zach
Removed:
accelerating, adjacent, adjustment, Albany, Alzheimer, Amit, angiopathy, Apothecon, Arazim, Arko, arresting, ASHP, attorney, Automation, Boxenbaum, brain, CC, cerebral, Chaim, Chicago, Cohen, Commissioner, concurrently, confirmation, consultancy, contemporaneously, deducting, designate, devalue, DeVry, dissolution, Donald, editorial, equivalence, expanding, fMRI, forMr, Genfit, GPhA, Graduate, Greenergy, Hadassah, hepatocyte, Hurvitz, inaugurated, John, Keller, Leader, leased, Lodgia, Maccabi, Magicjack, Marth, MD, MEDecide, Medtechnica, millioninvested, NATI, Netta, North, official, Oren, Paller, partnering, paymentin, pharmacist, Pharmacy, PhD, Philadelphia, plaque, Ran, Raveh, Ravid, Redhill, RESTORE, Rossetta, Rotex, round, Schwartz, Shire, Sorrento, SPA, Squibb, subcontractor, supplied, Tadea, Tadmor, Tamir, UIC, Vocaltec, William
Filing tables
Filing exhibits
Associated GLMD transcripts
GLMD similar filings
Filing view
External links
Exhibit 15.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-8 (Registration No. 333-206292 and 333-227441) and the Company’s Registration Statement on Form F-3 (Registration No. 333-223923) of our report dated March 18, 2021 relating to the consolidated financial statements of Galmed Pharmaceuticals Ltd., (the “Company”), which appear in the Company's Annual Report on Form 20-F for the year ended December 31, 2020.
|
| By: | /s/ Brightman Almagor Zohar & Co. |
| | | Brightman Almagor Zohar & Co. |
| | | A Firm in the Deloitte Global Network |
Date: March 18, 2021 | | | |